Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT…
Blueprint Medicines Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental new drug application for AYVAKIT (avapritinib) for the…
Read More...
Read More...
